In the motor cortex, loss of Betz cells was also confirmed. Synaptophysin immunostaining of the lumbosacral cord also revealed decreased expression outside the old lesions, excluding the posterior horn. Interestingly, decreased expression of synaptophysin was also evident in the cervical anterior horns, where no old lesions were observed. No Bunina bodies, TDP-43 inclusions, or Golgi fragmentation were found. Neurogenic atrophy was evident in the iliopsoas and scalenus muscles, and inclusion body myositis-like changes were also observed in these muscles and the tongue. Was it possible to have diagnosed this patient as having ALS? We consider that

the features in this case may have represented the pathology of long-standing and/or fatal PPS itself, and not ALS. “
“We describe a 78-year-old Japanese woman with early-stage progressive supranuclear palsy (PSP). She had a 3-week find more history of postural instability and gait disturbance. On examination, upper vertical gaze palsy, akinesia, hyperreflexia with pathological reflexes, hesitation, and postural instability were observed. Rigidity and resting tremors were not apparent. Brain MRI revealed atrophy of the frontotemporal GS-1101 purchase lobes and dilatation of the third ventricle. A month later, she died of cerebral infarction. The total duration

of her clinical course was approximately 2 months. The brain weighed 1180 g after fixation. Macroscopically, mild atrophy of the frontal lobes and mild depigmentation Tyrosine-protein kinase BLK of the substantia nigra were observed. The conspicuous findings included degeneration confined to the subthalamic nucleus and substantia nigra and widespread but infrequent tau-positive neurofibrillary tangles/pretangles and glial fibrillary tangles (tuft-shaped astrocytes, coiled bodies and argyrophilic threads)

in the brain. It has been reported that the most affected areas in PSP are the globus pallidus, subthalamic nucleus and substantia nigra. We suggest that degeneration in PSP would start with involvement of the substantia nigra and subthalamic nucleus. “
“Y. Liu, X. Zhang, Y. Liang, H. Yu, X. Chen, T. Zheng, B. Zheng, L. Wang, L. Zhao, C. Shi and S. Zhao (2011) Neuropathology and Applied Neurobiology37, 395–405 Targeting X box-binding protein-1 (XBP1) enhances sensitivity of glioma cells to oxidative stress Aims: Reactive oxygen species (ROS) and oxidative stress are tightly linked with cancers including gliomas. We previously reported the protective role of X box-binding protein-1 (XBP1) against oxidative stress in both mouse embryofibroblasts and human Hela cells. This study was to investigate XBP1-mediated protection against oxidative stress in the treatment of gliomas. Materials and methods: XBP1 expression levels were knocked down by siRNA transfection in the U251MG cell line.